Melanoma patients who respond to anti-CTLA-4 or anti-PD-1 therapy are also characterized by increased immunoproteasome expression associated with increased cytotoxic immune cell infiltration and upregulation of the IFN-γ pathway [61, 90]. The gene discussed is CTLA4; the disease is melanoma.